Published in J Virol on March 31, 2010
HIV mono-infection is associated with FIB-4 - A noninvasive index of liver fibrosis - in women. Clin Infect Dis (2011) 1.37
Host factors involved in hepatitis B virus maturation, assembly, and egress. Med Microbiol Immunol (2012) 1.06
Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. PLoS One (2013) 0.96
Low-level HIV infection of hepatocytes. Virol J (2012) 0.81
In vitro replication phenotype of a novel (-1G) hepatitis B virus variant associated with HIV co-infection. J Med Virol (2012) 0.81
Effects of HCV on basal and tat-induced HIV LTR activation. PLoS One (2013) 0.81
HIV Infection and TLR Signalling in the Liver. Gastroenterol Res Pract (2012) 0.79
HIV-1 Nef is transferred from expressing T cells to hepatocytic cells through conduits and enhances HCV replication. PLoS One (2014) 0.79
HBV and HIV co-infection: Impact on liver pathobiology and therapeutic approaches. World J Hepatol (2015) 0.77
HIV variability in the liver and evidence of possible compartmentalization. AIDS Res Hum Retroviruses (2011) 0.77
Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients. AIDS Res Hum Retroviruses (2013) 0.75
Hepatitis B virus surface antigen seroconversion in HIV-infected individual after pegylated interferon-alpha treatment: a case report. J Venom Anim Toxins Incl Trop Dis (2013) 0.75
HIV Vpr protein upregulates microRNA-122 expression and stimulates hepatitis C virus replication. J Gen Virol (2015) 0.75
HIV infection of hepatocytes results in a modest increase in hepatitis C virus expression in vitro. PLoS One (2014) 0.75
Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science (1992) 5.61
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med (1998) 4.77
The role of envelope proteins in hepatitis B virus assembly. Proc Natl Acad Sci U S A (1991) 4.37
Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell (1989) 3.60
Is green fluorescent protein toxic to the living cells? Biochem Biophys Res Commun (1999) 3.00
Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother (1997) 2.84
Trans-activation of the human immunodeficiency virus long terminal repeat by the hepatitis B virus X protein. Proc Natl Acad Sci U S A (1988) 2.79
Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology (1999) 2.63
Cellular vacuolization and apoptosis induced by hepatitis B virus large surface protein. Hepatology (2002) 2.34
Activation of hepatitis B virus S promoter by the viral large surface protein via induction of stress in the endoplasmic reticulum. J Virol (1997) 1.56
Human immunodeficiency virus type 1 Gag engages the Bro1 domain of ALIX/AIP1 through the nucleocapsid. J Virol (2007) 1.48
HCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver? J Viral Hepat (2008) 1.45
Molecular virology of hepatitis B virus. Semin Liver Dis (2004) 1.45
The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology (2008) 1.41
Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specific pre-S mutants that may induce endoplasmic reticulum stress. Am J Pathol (2003) 1.39
CD4-independent, productive human immunodeficiency virus type 1 infection of hepatoma cell lines in vitro. J Virol (1990) 1.34
Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism. J Infect Dis (2003) 1.33
Hepatitis B virus maturation is sensitive to functional inhibition of ESCRT-III, Vps4, and gamma 2-adaptin. J Virol (2007) 1.32
Identification and quantitation of HIV-1 in the liver of patients with AIDS. AIDS (1992) 1.30
Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness. J Virol Methods (2006) 1.26
Intracellular retention of surface protein by a hepatitis B virus mutant that releases virion particles. J Virol (1996) 1.25
Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy. J Virol (2005) 1.23
Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology (2002) 1.22
Ground glass hepatocytes contain pre-S mutants and represent preneoplastic lesions in chronic hepatitis B virus infection. J Gastroenterol Hepatol (2008) 1.11
Neuropathologic and neuroinflammatory activities of HIV-1-infected human astrocytes in murine brain. Glia (2006) 0.97
HIV induces TRAIL sensitivity in hepatocytes. PLoS One (2009) 0.97
CREB/PKA sensitive signalling pathways activate and maintain expression levels of the hepatitis B virus pre-S2/S promoter. Gut (2005) 0.90
Regulation by dimethylsulfoxide, insulin, and corticosteroids of hepatitis B virus replication in a transfected human hepatoma cell line. J Med Virol (1989) 0.89
Primary T-lymphocytes rescue the replication of HIV-1 DIS RNA mutants in part by facilitating reverse transcription. Nucleic Acids Res (2008) 0.88
Translational selection in the expression of the hepatitis B virus envelope proteins. DNA (1989) 0.81
Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis (2011) 7.41
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol (2002) 4.63
The end of AIDS: HIV infection as a chronic disease. Lancet (2013) 3.96
Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood (2003) 3.40
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology (2004) 3.19
Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol (2010) 2.61
Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust (2009) 2.42
The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol (2013) 2.41
The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol (2007) 2.41
Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response. Immunol Cell Biol (2007) 2.24
Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. J Infect Dis (2009) 2.24
CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood (2007) 2.21
Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B. Liver Int (2010) 2.12
ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. Hepatology (2014) 2.12
Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton. Proc Natl Acad Sci U S A (2010) 2.07
Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology (2010) 2.02
Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1 implications for EBV-mediated immortalization. Mol Cell (2005) 1.92
SINGLE-01: a randomized, controlled trial comparing the efficacy and depth of insertion of single- and double-balloon enteroscopy by using a novel method to determine insertion depth. Gastrointest Endosc (2012) 1.91
Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res (2003) 1.88
Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis (2011) 1.77
IMGT/HighV QUEST paradigm for T cell receptor IMGT clonotype diversity and next generation repertoire immunoprofiling. Nat Commun (2013) 1.71
Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. J Hepatol (2009) 1.67
Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation. J Infect Dis (2010) 1.63
HDAC inhibitors in HIV. Immunol Cell Biol (2011) 1.59
Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors. J Gastroenterol Hepatol (2007) 1.54
Initial experience with capsule endoscopy at a major referral hospital. Med J Aust (2003) 1.54
Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother (2013) 1.53
Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology (2002) 1.53
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology (2008) 1.52
The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS (2008) 1.50
Prospective study of the clinical impact of EUS. Gastrointest Endosc (2005) 1.49
Protein interaction domains of the ubiquitin-specific protease, USP7/HAUSP. J Biol Chem (2003) 1.47
Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol (2006) 1.47
Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome. AIDS (2013) 1.46
Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major. Am J Gastroenterol (2002) 1.45
BK virus-associated progressive multifocal leukoencephalopathy. Med J Aust (2013) 1.41
Noninvasive imaging of the small bowel in Crohn's disease: the final frontier. Inflamm Bowel Dis (2011) 1.40
CD4+ T-cell deficiency in HIV patients responding to antiretroviral therapy is associated with increased expression of interferon-stimulated genes in CD4+ T cells. J Infect Dis (2011) 1.40
The evidence for a change in antenatal HIV screening policy in Australia. Med J Aust (2006) 1.40
Variable uptake of recommended interventions to reduce mother-to-child transmission of HIV in Australia, 1982-2005. Med J Aust (2008) 1.37
The EBNA1 protein of Epstein-Barr virus functionally interacts with Brd4. J Virol (2008) 1.35
Both CD31(+) and CD31⁻ naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. J Infect Dis (2010) 1.33
The intracellular granzyme B inhibitor, proteinase inhibitor 9, is up-regulated during accessory cell maturation and effector cell degranulation, and its overexpression enhances CTL potency. J Immunol (2003) 1.32
Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells. Retrovirology (2011) 1.31
Resistance to anti-HCV protease inhibitors. Curr Opin Virol (2011) 1.30
96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol (2007) 1.28
Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology (2002) 1.28
Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology (2005) 1.28
Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis (2006) 1.27
HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir Ther (2011) 1.26
A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics. Antivir Ther (2008) 1.25
Persistent immune activation in chronic HIV infection: do any interventions work? AIDS (2013) 1.24
Postoperative recurrent luminal Crohn's disease: a systematic review. Inflamm Bowel Dis (2011) 1.24
Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy. J Virol (2005) 1.23
The effect of erythromycin on video capsule endoscopy intestinal-transit time. Gastrointest Endosc (2006) 1.22
Immune restoration diseases reflect diverse immunopathological mechanisms. Clin Microbiol Rev (2009) 1.21
Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology (2003) 1.21
Identification of lineage relationships and novel markers of blood and skin human dendritic cells. J Immunol (2012) 1.21
Chemokine levels and chemokine receptor expression in the blood and the cerebrospinal fluid of HIV-infected patients with cryptococcal meningitis and cryptococcosis-associated immune reconstitution inflammatory syndrome. J Infect Dis (2013) 1.18
Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Antivir Ther (2010) 1.18
Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo. Retrovirology (2007) 1.17
HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism. J Virol (2011) 1.16
SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B. Antiviral Res (2006) 1.16
Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis (2013) 1.16
Regulation of the EBNA1 Epstein-Barr virus protein by serine phosphorylation and arginine methylation. J Virol (2006) 1.16
Differential expression of CD163 on monocyte subsets in healthy and HIV-1 infected individuals. PLoS One (2011) 1.15